ES2531368T3 - Métodos y kits para diagnosticar tumorigenicidad y determinar resistencia a los efectos antineoplásicos de la terapia antiestrógeno - Google Patents

Métodos y kits para diagnosticar tumorigenicidad y determinar resistencia a los efectos antineoplásicos de la terapia antiestrógeno Download PDF

Info

Publication number
ES2531368T3
ES2531368T3 ES02741997T ES02741997T ES2531368T3 ES 2531368 T3 ES2531368 T3 ES 2531368T3 ES 02741997 T ES02741997 T ES 02741997T ES 02741997 T ES02741997 T ES 02741997T ES 2531368 T3 ES2531368 T3 ES 2531368T3
Authority
ES
Spain
Prior art keywords
tumorigenicity
cells
diagnose
kits
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES02741997T
Other languages
English (en)
Inventor
Ginette Serrero
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
A&G Pharmaceutical Inc
Original Assignee
A&G Pharmaceutical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by A&G Pharmaceutical Inc filed Critical A&G Pharmaceutical Inc
Application granted granted Critical
Publication of ES2531368T3 publication Critical patent/ES2531368T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measurement Of Resistance Or Impedance (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)

Abstract

Un método para diagnosticar la tumorigenicidad del cáncer de mama en un paciente humano, que comprende: i. detectar GP88 en células de una muestra biológica obtenida de un paciente; ii. determinar el número de células positivas para GP88 en dicha muestra; y iii. determinar la proporción de células positivas para GP88 respecto al número total de células en dicha muestra biológica, en el que dicha proporción es indicativa de la tumorigenicidad del cáncer de mama, y en el que la muestra biológica que contiene las células de dicho paciente es una muestra de tejido de mama; GP88 en dichas células de dicho tejido de mama se detecta por inmunotinción con anticuerpo anti-GP88 humano; el número de células positivas para GP88 en dicha muestra se determina por examen microscópico; y una proporción de al menos 10% de células positivas para GP88 respecto al número total de células en dicho tejido de mama indica la tumorigenicidad del cáncer de mama.
ES02741997T 2001-06-15 2002-06-14 Métodos y kits para diagnosticar tumorigenicidad y determinar resistencia a los efectos antineoplásicos de la terapia antiestrógeno Expired - Lifetime ES2531368T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/880,842 US6881548B2 (en) 1997-05-23 2001-06-15 Methods and kits for diagnosing tumorigenicity and determining resistance to the antineoplastic effects of antiestrogen therapy
PCT/US2002/018549 WO2002102229A2 (en) 2001-06-15 2002-06-14 Diagnosing tumorigenicity and determining resistance to anticancer therapy

Publications (1)

Publication Number Publication Date
ES2531368T3 true ES2531368T3 (es) 2015-03-13

Family

ID=25377233

Family Applications (2)

Application Number Title Priority Date Filing Date
ES02739838T Expired - Lifetime ES2359494T3 (es) 2001-06-15 2002-06-14 Procedimientos y composiciones para inhibir, prevenir o reducir el crecimiento celular tumoral en los pacientes resistentes a los efectos antineoplásicos de la trerapia antiestrogénica.
ES02741997T Expired - Lifetime ES2531368T3 (es) 2001-06-15 2002-06-14 Métodos y kits para diagnosticar tumorigenicidad y determinar resistencia a los efectos antineoplásicos de la terapia antiestrógeno

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES02739838T Expired - Lifetime ES2359494T3 (es) 2001-06-15 2002-06-14 Procedimientos y composiciones para inhibir, prevenir o reducir el crecimiento celular tumoral en los pacientes resistentes a los efectos antineoplásicos de la trerapia antiestrogénica.

Country Status (11)

Country Link
US (1) US6881548B2 (es)
EP (2) EP1404365B1 (es)
JP (5) JP4348178B2 (es)
KR (3) KR101258254B1 (es)
CN (2) CN101584862B (es)
AT (1) ATE496635T1 (es)
AU (2) AU2002315060B2 (es)
CA (2) CA2450666A1 (es)
DE (1) DE60239059D1 (es)
ES (2) ES2359494T3 (es)
WO (2) WO2002102306A2 (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7091047B2 (en) * 1997-05-23 2006-08-15 A&G Pharmaceutical, Inc. Methods and kits for diagnosing tumorigenicity
US6881548B2 (en) * 1997-05-23 2005-04-19 A&G Pharmaceutical, Inc. Methods and kits for diagnosing tumorigenicity and determining resistance to the antineoplastic effects of antiestrogen therapy
US20100111928A1 (en) * 1997-05-23 2010-05-06 A & G Pharmaceutical, Inc. Methods and kits for diagnosis tumorgenicity
US8512960B2 (en) * 1997-05-23 2013-08-20 A&G Pharmaceutical, Inc. 88kDa tumorigenic growth factor and antagonists
US20030215445A1 (en) 1997-05-23 2003-11-20 Ginette Serrero Methods and compositions for inhibiting the growth of hematopoietic malignant cells
US6309826B1 (en) 1997-05-23 2001-10-30 Ginette Serrero 88kDa tumorigenic growth factor and antagonists
US20030219818A1 (en) * 2002-05-10 2003-11-27 Bohen Sean P. Methods and compositions for determining neoplastic disease responsiveness to antibody therapy
US7411045B2 (en) * 2002-11-19 2008-08-12 A&G Pharmaceutical, Inc. Autocrine growth factor receptor antibodies and methods
DE60334499D1 (de) * 2003-02-26 2010-11-18 A & G Pharmaceuticals Inc Verfahren zur erhöhung der ausbreitung von b-zellen
EP1849480A3 (en) * 2003-06-23 2013-06-26 A & G Pharmaceutical, Inc. Compositions and methods for restoring sensitivity of tumor cells to antitumor therapy and inducing apoptosis
CA2530582C (en) * 2003-06-23 2014-09-09 A&G Pharmaceutical, Inc. Compositions and methods for restoring sensitivity of tumor cells to antitumor therapy and inducing apoptosis
EP1660010B1 (en) * 2003-08-01 2013-07-24 A & G Pharmaceutical, Inc. Compositions and methods for restoring sensitivity to treatment with her2 antagonists
EP2173981B1 (en) 2007-06-13 2018-07-18 3M Innovative Properties Company Securable mounting material and method of making and using the same
US8617475B2 (en) 2007-06-13 2013-12-31 3M Innovative Properties Company Erosion resistant mounting material and method of making and using the same
WO2009134944A2 (en) * 2008-04-29 2009-11-05 Nodality, Inc. Methods of determining the health status of an individual
CN107085108A (zh) * 2008-09-05 2017-08-22 A&G药品公司 诊断癌症和确定癌症患者的总体生存和无病生存的方法
KR102094326B1 (ko) 2012-05-03 2020-03-30 미디얼 리서치 리미티드 위장암의 위험을 평가하는 방법 및 시스템
JP6148540B2 (ja) * 2013-06-07 2017-06-14 株式会社島津製作所 質量分析装置を用いたグラニュリンペプチドの定量分析方法、および分析用プログラム
WO2017011623A1 (en) * 2015-07-14 2017-01-19 Atossa Genetics Inc. Transpapillary methods and compositions for treating breast disorders
SG11202002105WA (en) 2017-09-11 2020-04-29 Atossa Therapeutics Inc Methods for making and using endoxifen
US20220362771A1 (en) * 2018-07-13 2022-11-17 Hifibio Sas Use of droplet single cell epigenome profiling for patient stratification
JP7662204B2 (ja) 2019-07-03 2025-04-15 アトッサ・セラピューティクス・インコーポレイテッド エンドキシフェンの徐放性組成物
EP4449926B1 (en) 2023-04-18 2026-04-08 Shiro Helmets, S.A. Helmet with chin guard

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5416192A (en) 1990-04-03 1995-05-16 Bristol-Myers Squibb Company Epithelins: novel cysteine-rich growth modulating proteins
CA2023030A1 (en) * 1990-07-13 1992-01-14 Robert R. Guerrero In vitro method and probe for detecting the presence of the ring shaped particle and malignancy in humans and animals
US6309826B1 (en) * 1997-05-23 2001-10-30 Ginette Serrero 88kDa tumorigenic growth factor and antagonists
US6881548B2 (en) * 1997-05-23 2005-04-19 A&G Pharmaceutical, Inc. Methods and kits for diagnosing tumorigenicity and determining resistance to the antineoplastic effects of antiestrogen therapy
ES2228932T3 (es) * 2000-08-11 2005-04-16 Wyeth Procedimiento de tratamiento del carcinoma positivo de estrogenos.

Also Published As

Publication number Publication date
KR20100050580A (ko) 2010-05-13
ATE496635T1 (de) 2011-02-15
CN100397081C (zh) 2008-06-25
KR20090045423A (ko) 2009-05-07
CN1682111A (zh) 2005-10-12
US20020025543A1 (en) 2002-02-28
JP4392238B2 (ja) 2009-12-24
CN101584862B (zh) 2016-04-06
WO2002102306A2 (en) 2002-12-27
KR20040043128A (ko) 2004-05-22
JP2005524602A (ja) 2005-08-18
KR100972053B1 (ko) 2010-07-23
WO2002102306A8 (en) 2004-05-21
WO2002102306A3 (en) 2003-06-05
WO2002102229A3 (en) 2003-10-30
JP2005514907A (ja) 2005-05-26
WO2002102229A9 (en) 2008-07-10
KR101258254B1 (ko) 2013-04-25
HK1083366A1 (zh) 2006-06-30
EP1399739A2 (en) 2004-03-24
WO2002102229A2 (en) 2002-12-27
JP2009215302A (ja) 2009-09-24
EP1404365B1 (en) 2011-01-26
ES2359494T3 (es) 2011-05-24
CA2450590A1 (en) 2002-12-27
DE60239059D1 (de) 2011-03-10
JP4348178B2 (ja) 2009-10-21
EP1399739B1 (en) 2014-11-26
AU2002315060B2 (en) 2007-07-12
EP1399739A4 (en) 2006-07-19
EP1404365A2 (en) 2004-04-07
JP2015227369A (ja) 2015-12-17
CN101584862A (zh) 2009-11-25
CA2450666A1 (en) 2002-12-27
JP2013139473A (ja) 2013-07-18
US6881548B2 (en) 2005-04-19
KR100980105B1 (ko) 2010-09-07
AU2002312462B2 (en) 2007-08-30
EP1404365A4 (en) 2006-04-12

Similar Documents

Publication Publication Date Title
Russell et al. Polyamines as predictors of success and failure in cancer chemotherapy
AR107561A2 (es) Ensayo elisa para la detección de vegf
Lee et al. Highly selective two-photon imaging of cysteine in cancerous cells and tissues
EP1640458A4 (en) METHOD FOR SELECTING PATIENTS SUITABLE FOR THE WT1 VACCINE
BRPI0412725A (pt) marcadores para detecção de cáncer gástrico
MX2007005053A (es) Metodo para evaluar la enfermedad de alzheimer y reactivo de diagnostico.
BR0317394A (pt) Uso de nicotinamida n-metiltransferase como um marcador para câncer colorretal
RU2010101909A (ru) Способ выявления или лечения реакции "трансплантат против хозяина"
ATE447715T1 (de) Automatische glykofingerabdruck-strategie
BR112012007561A2 (pt) padrões de desenvolvimento de fibroblasto para diagnóstico de doença de alzheimer
EP1399739A4 (en) METHOD AND KITS FOR DIAGNOSIS OF TUMOR ENGENITATION AND DETERMINATION OF RESISTANCE TO THE ANTINEOPLASTIC EFFECTS OF ANTI-STROGEN THERAPY
PA8796101A1 (es) Analisis de enfermedades infecciosas en fluido menstrual, celulas endometriales/menstruales, fluido amniotico, sangre de cordon umbilical u otras muestras
DE602004025676D1 (de) Verfahren zur untersuchung einer zelle
RU2008103988A (ru) Способ диагностики рассеяного склероза
ES2570609T3 (es) Método para someter a ensayo la aminoacilasa 1 para el diagnóstico in vitro del cáncer colorrectal
FR2846426B1 (fr) Procede de dosage du ngf pour le diagnostic in vitro du cancer du sein et utilisation en therapie
EP2385375A3 (en) Development and use of fluorescent probes of unbound analytes
CN108957004A (zh) 检测H3K9me2和H3K36me3表达量的试剂在制备胃癌预后评估试剂盒中的应用
BR0209681A (pt) Método e kit para o diagnóstico in vivo ou para o monitoramento de uma doença que envolve uma reação inflamatória dentro de um paciente
ATE466285T1 (de) Diagnose von leberzirrhose mittels eines für menschliches protoonkogenes protein spezifischen antikörpers
AR068449A1 (es) Analisis de enfermedades infecciosas en fluido menstrual, celulas endometriales / menstruales , fluido amniotico , sangre de cordon umbilical u otras muestras
EP1988164A4 (en) METHOD FOR TESTING THE SENSITIVITY OF A SOLID TUMOR AGAINST TYROSINE KINASE INHIBITOR AND TEST KIT THEREFOR
US20240157358A1 (en) Biosensing system and method for in-situ determination of metastasis in a sample
TW202102854A (zh) 評估皮膚狀態的方法
BRPI0415562B8 (pt) método in vitro para avaliação prognóstica de carcinoma de ovário em um paciente, e, kit de imunoensaio